Lebrikizumab (TNX-650) is a humanized IgG4 monoclonal antibody that targets interleukin-13 (IL-13), binding specifically to a non-receptor binding domain of IL-13 to inhibit its activity. This antibody effectively blocks the IL-13-driven Th2 inflammatory response by interfering with the signaling pathway involving IL-4R??/IL-13R??1. Lebrikizumab also exhibits anti-itch properties, making it a valuable tool for research into asthma, atopic dermatitis, and neuroinflammatory disorders.
Lebrikizumab (TNX-650) is a humanized IgG4 monoclonal antibody that targets interleukin-13 (IL-13), binding specifically to a non-receptor binding domain of IL-13 to inhibit its activity. This antibody effectively blocks the IL-13-driven Th2 inflammatory response by interfering with the signaling pathway involving IL-4R??/IL-13R??1. Lebrikizumab also exhibits anti-itch properties, making it a valuable tool for research into asthma, atopic dermatitis, and neuroinflammatory disorders.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
